Randomised controlled trial of three burns dressings for partial thickness burns in children

Gee Kee E L, Kimble R M, Cuttle L, Khan A, Stockton K A Burns 2015, 41: 946-55

Aims

To determine whether one of three dressing regimes would be more effective in the treatment of partial thickness burns in children in terms of:

- healing time,
- pain and distress at dressing changes

Method

Prospective, randomised controlled trial

Children (0-15 years) with clean ≤10% total body surface area (TBSA) partial thickness burns who met the inclusion criteria were randomised to one of three intervention groups:

- 1. Acticoat[◊]
- 2. Acticoat^{\epsilon} with Mepitel[®]
- 3. Mepilex[®] Ag

Results

No infections were detected for the course of the study in any of the three groups.



Pain at dressing change (*FLACC score)
Pain and anxiety at dressing removal
Acticoat [¢]
Mepilex Ag 32% lower
Pain and anxiety at dressing application
Acticoat*
Mepilex Ag 37% lower
Mepilex® Ag is associated with less pain during dressing changes: 32% lower pain and anxiety at dressing removal compared to Acticoat®. 37% lower pain and anxiety at dressing application when compared to Acticoat.

Application time

Cumulative dressing removal and application time on the first dressing change was significantly faster in the Mepilex Ag group compared to Acticoat⁶ and Acticoat⁶ with Mepitel.

Mepilex Ag is an effective silver-containing dressing in terms of accelerated wound re-epithelialisation time (compared to Acticoat[°] and Acticoat[°] with Mepitel) and decreased pain during dressing changes (compared to Acticoat[°]), for clean, <10% TBSA partial thickness burns in children.

*FLACC = Face Legs, Arms, Cry and Consolability pain score tool.

Outcomes measured

Primary outcome measures

Days to re-epithelialisation – assessed by:

- Clinical judgement,
- Use of Visitrak™ grids
- Analysis of 3D camera photographs and
- Blinded review of photographs.

Pain and distress – assessed by:

- Patient's self-report of pain intensity using the Faces Pain Scale-Revised (FPS-R) (if patient was ≥3 years),
- Nurse's observational rating of patient's pain and distress using the face, legs, activity, cry, consolability (FLACC) scale,
- Patient's self-report (if >8 years) or the parent's report of the
- patient's pain intensity using a Visual Analog Scale-Pain (VAS-P)Pulse rate and
- Respiratory rate (taken immediately prior to and after dressing changes).

*using 5-point Likert scales

Additional results

- 103 children were randomised into the study:
 - Acticoat⁽ⁿ⁼³³⁾
 - Acticoat^{\equiv with Mepitel (n=34)}
 - Mepilex Ag (n=36)
- As per the intention to treat protocol, 96 children were included for analysis
- There was no statistically significant difference between the dressing groups with respect to baseline variables (age, gender, burn depth, wound perfusion units, TBSA, mechanism and location of burn)

Healing time

Raw data	N	Median	IQR	
Acticoat [¢]	28	9.50	7.00 - 14.00	
Acticoat [¢] with Mepitel	28	10.00	8.00 - 13.00	
Mepilex Ag	32	7.00	4.00 - 8.00	Kav
Adjusted for burn depth	IRR	95% CI	p-value	N – number
Acticoat [◊] vs Mepilex Ag	1.40	1.14 – 1.73	<0.01	IQR – inter-
Acticoat ^{\$} with Mepitel vs Mepilex Ag	1.33	1.08 – 1.63	0.01	CI – confidence interva

Pain and distress compared to Acticoat[¢]

Measure	Groups	After dressing removal	After dressing application		
FLACC scores	Mepilex Ag	32% lower (p=0.01)	37% lower (p=0.04)		
	Acticoat ^{\o} with Mepitel	23% lower (p=0.04)	40% lower (p=<0.01)		
VAS-P scores	Mepilex Ag	25% lower (p=0.04)	30% lower (p=0.06)		
	Acticoat [¢] with Mepitel	24% lower (p=0.07)	34% lower (p=0.02)		
Pulse rates	Mepilex Ag	7% lower (p=0.01)	9% lower (p=0.03)		
	Acticoat [¢] with Mepitel	8% lower (p←0.01)	7% lower (p=0.02)		
FPS-R scores	Modelling was not completed due to large amount of missing data (majority of subjects were too young to use the scale).				
Respiratory rates	No significant difference between the three groups.				

Secondary outcome measures

The following were measured at dressing changes:

- Patient's physical function while wearing the dressing (first dressing change only)*,
- Nurse's view on ease of removal and application of the dressing*,
- Adverse events.

www.molnlycke.com.au | www.molnlycke.co.nz

You will be required to input the following code 1FtYrV or your AHPRA registration number to access our websites.

Mölnlycke, 12 Narabang Way, Level 4, Belrose, NSW, 2085. Phone 1800 005 231. New Zealand Orders & Enquiries 0800 005 231, www.molnlycke.co.nz. The Mölnlycke, Mepitel and Mepilex trademarks, names and logos are registered globally to one or more of the Mölnlycke Health Care Group of Companies. ©2023 Mölnlycke Health Care. All rights reserved. AUWC_000488



